Darbepoetin alfa: an effective treatment for chemotherapy-related anemia
Alexandra King
This article has no abstract so we have provided the first paragraph of the full text.
The novel erythropoetic protein darbepoetin alfa exhibits enhanced biological activity and increased serum half-life compared with other erythropoetic agents used to treat chemotherapy-related anemia. Bartsch et al.'s prospective phase II trial has evaluated the effect of darbepoetin alfa on the hemoglobin (Hb) levels of patients undergoing chemotherapy for various malignancies.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Biogeochemistry Iron findingsNature News and Views (26 Apr 2007)
Mal-function of TLRs by SOCSNature Immunology News and Views (01 Feb 2006)
Solar size variationNature News and Views (31 Jul 1980)